What is Pixium Vision S.A. (PXMVF)?

Pixium Vision S.A. (PXMVF) is a stock in the Healthcare sector, Medical - Instruments & Supplies industry. View full analysis on Stocks360.

What is the current price of PXMVF?

The current price of PXMVF is $1.50. Prices are updated in real time on Stocks360.

What is PXMVF's price-to-earnings (PE) ratio?

PXMVF's trailing twelve-month PE ratio is -6.69, based on current price and earnings per share data available on Stocks360.

What is PXMVF's market capitalization?

PXMVF's market capitalization is $4,618,140.00, placing it in the small-cap tier.

Pixium Vision S.A. (PXMVF)

Stock analysis · OTC · Healthcare · Medical - Instruments & Supplies

$1.50

Market Cap

$4.62M

PE (TTM)

-6.69

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.97

Day Range

$0.03 – $1.50

52-wk Range

$0.03 – $1.50

Avg Volume

N/A

Volume

16.75K

Pixium Vision S.A. (PXMVF) is a publicly traded company in the Healthcare sector. Latest price: $1.50. Market cap $4.62M. Trailing PE -6.69. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Pixium Vision S.A.

Pixium Vision S.A., established in Paris, France, in 2011, is a pioneering firm specializing in bioelectronics and brain-machine interface technologies, with a particular emphasis on neuromodulation. The company's flagship product is the PRIMA System, an advanced bionic vision solution designed to restore sight for individuals experiencing profound vision impairment. This often includes patients with retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD), as well as other conditions leading to blindness. The PRIMA System functions by circumventing the damaged natural photoreceptor cells and instead electrically stimulating the inner retina's nerve cells, which then convey visual data via the optic nerve directly to the brain. Pixium Vision S.A. actively collaborates with a network of distinguished institutions, including Stanford University, the Institut de la Vision, Moorfields Eye Hospital, the Institute of Ocular Microsurgery, University Hospital, and UPMC.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-6.69×
P/S (TTM)	2060.15×
P/B	-22.96×
P/FCF (TTM)	-0.36×
EV / EBITDA	-0.65×
EV / Sales	3756.00×
Earnings Yield	-14.63%
Free Cash Flow Yield	-277.16%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$7.51M
Revenue (TTM)	$2.00K
Net Income (TTM)	-$602.61K
Free Cash Flow (TTM)	-$10.81M
Net Debt	$3.39M
Working Capital	$1.65M
Gross Margin	-40274.55%
Operating Margin	-597250.00%
Net Margin	-478473.75%
Return on Equity	-645.71%
Return on Invested Capital	-143.50%